The efficacy and safety of switching from linagliptin to once-weekly dulaglutide in hemodialysis patients with type 2 diabetes mellitus (pilot study)
Not Applicable
Recruiting
- Conditions
- Type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000021944
- Lead Sponsor
- Minamisenju Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with severe gastroparesis 2)The patient with the medical history of the pancreatitis 3)Patients who have a medical history of hypersensitivity 4)Pregnant or possibly pregnant women and women on lactation 5)Ineligible patients according to the investigator's judgment 6)The patients who do not agree with this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The amount changes of glycoalbuin and hemoglobin A1c for 26 weeks The amount changes of daily use insulin in the patients who treated with insulin for 26 weeks
- Secondary Outcome Measures
Name Time Method The amount changes of glycoalbuin and hemoglobin A1c for 12 weeks The amount changes of average body weight before dialysis for one week, self monitoring blood glucose, plasma glucose before hemodialysis, UA, TG, HDL-Cho, LDL-Cho, C-peptide, adverse events